^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IBI-389

    i
    Associations
    News

    Trials

    Company:
    Innovent Biologics
    Drug class:
    CD3 agonist, CLDN18.2 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies (NCT05164458)
    Phase 1
    Innovent Biologics (Suzhou) Co. Ltd.
    Recruiting
    Last update posted :
    12/28/2023
    Initiation :
    03/22/2022
    Primary completion :
    04/30/2024
    Completion :
    09/30/2024
    CLDN18
    |
    CLDN18.2 expression
    |
    Tyvyt (sintilimab) • IBI-389